Comparison of the Safety and Efficacy of Dorzolamide 2% and Brimonidine 0.2% in Patients with Glaucoma or Ocular Hypertension

Journal of Glaucoma

Volumn 13, Issue 2, 2004, Pages 168-173

  Whitson, Jess T ^a   Henry, Charles ^b   Hughes, Bret ^c   Lee, David A ^d   Terry, Stuart ^e   Fechtner, Robert D ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Little Rock Eye Clinic   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Brimonidine; Dorzolamide; Glaucoma; Intraocular pressure; Monotherapy

Indexed keywords

BRIMONIDINE; DORZOLAMIDE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRY EYE; EYE BURNING; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADRENERGIC ALPHA-AGONISTS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOXALINES; SAFETY; SULFONAMIDES; THIOPHENES; TREATMENT OUTCOME;

EID: 1642278078     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200404000-00015     Document Type: Article

References (19)

1. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110:498-499.
2. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;(Suppl 1): S19-S26.
3. Konstas AG, Stewart WC, Topouzis F, et al. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol. 2001;131:729-733.
4. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther. 2001: 604-619.
5. Cantor LB, Katz W, Flartey KJ, et al. Comparison of the effect of Alphagan 0.2% versus Trusopt 2% in combination with beta-blockers. Invest Ophthalmol Vis Sci. 1998;39(Suppl):480.
6. Stewart WC, Sharpe ED, Holmes KT, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol. 2000;129:723-727.
7. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.
8. Becker B. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:487-488.
9. Bergea B, Bodin L, Swedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999; 106:997-1004.
10. Book SA. Essentials of Statistics. New York: McGraw Hill; 1978:117-122, 205-215.
11. SAS Procedure Guide. Version 8. Cary, North Carolina: SAS Inc.; 2000.
12. Rosner B. Fundamentals of Biostatistics. Boston: Duxbury Press; 1986: 336-341.
13. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995;113:1009-1011.
14. Strahlman E, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. Am J Ophthalmol. 1996;122: 183-194.
15. Rusk C, Sharpe E, Laurence J, et al. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group. Clin Ther. 1998; 20:454-466.
16. Javitt JC, Schiffman RM. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. J Glaucoma. 2000;9:224-234.
17. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999;127:20-26.
18. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 1998;105:1960-1967.
19. Boyle JE, Ghosh K, Gieser DK. A randomized trial comparing the dorzolamide-timolol combination twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105:1945-1951.